Who are HBI-8000 in combination with nivolumab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hbi-8000-in-combination-with-nivolumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

HBI-8000 in combination with nivolumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HBI-8000 in combination with nivolumab (HBI-8000 in combination with nivolumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HDAC inhibitor (in combination with PD-1 inhibitor). Area: Oncology.

phase 3 HDAC inhibitor (in combination with PD-1 inhibitor) Histone deacetylase (HDAC); combined with PD-1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

HBI-8000 in combination with nivolumab (HBI-8000 in combination with nivolumab) — HUYABIO International, LLC.. HBI-8000 is a histone deacetylase (HDAC) inhibitor that enhances immune response when combined with nivolumab, a PD-1 checkpoint inhibitor.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
HBI-8000 in combination with nivolumab TARGET	HBI-8000 in combination with nivolumab	HUYABIO International, LLC.	phase 3	HDAC inhibitor (in combination with PD-1 inhibitor)	Histone deacetylase (HDAC); combined with PD-1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HDAC inhibitor (in combination with PD-1 inhibitor) class)

HUYABIO International, LLC. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HBI-8000 in combination with nivolumab — Competitive Intelligence Brief. https://druglandscape.com/ci/hbi-8000-in-combination-with-nivolumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab